Anlon Healthcare IPO – Assessment, Date, Value, GMP, Evaluation – Ought to You Subscribe or Keep away from?

Anlon Healthcare Restricted is popping out with its Preliminary Public Providing (IPO). This IPO has generated vital curiosity amongst buyers, given the corporate’s sturdy presence within the pharmaceutical intermediates and Lively Pharmaceutical Elements (APIs) enterprise. On this detailed Anlon Healthcare IPO Assessment, we are going to cowl the IPO Date, Value, GMP, Subject Measurement, Aggressive Strengths, Financials, P/E ratio comparability with friends, Gray Market Premium, and supply our evaluation on whether or not buyers ought to subscribe or keep away from this IPO.

About Anlon Healthcare Ltd

Integrated in 2013, Anlon Healthcare Restricted is a chemical manufacturing firm engaged within the manufacturing of Pharma Intermediates and APIs. The corporate manufactures high-purity intermediates and APIs that cater to pharmaceutical formulations, nutraceuticals, private care, and animal well being merchandise.

Key highlights of its enterprise:

• Over 65 commercialized merchandise, 28 in pilot stage, and 49 in laboratory testing.
• Sturdy deal with customized manufacturing for complicated chemical compounds with excessive purity requirements.
• Holds 21 Drug Grasp File (DMF) approvals globally together with ANVISA, NMPA, and PMDA.
• Has a group of 105 staff with 34 in R&D and high quality management.

Aggressive Strengths

• Sturdy Product Portfolio: Big selection of APIs and intermediates catering to a number of industries.
• Skilled Promoters & Administration: Promoted by Punitkumar R. Rasadia, Meet Atulkumar Vachhani, and Mamata Punitkumar Rasadia.
• Excessive Entry Boundaries: Lengthy buyer approval cycles and strict product high quality requirements.
• Regulatory Approvals: International recognition with a number of DMF filings.
• Deal with High quality & Security: In-house high quality management labs and deal with Atmosphere, Well being, and Security (EHS).

Anlon Healthcare IPO Subject Particulars

• IPO Date: August 26, 2025 to August 29, 2025
• Itemizing Date: September 3, 2025 (Tentative)
• IPO Value Band: ₹86 to ₹91 per share
• Lot Measurement: 164 shares
• Subject Measurement: 1.33 crore shares aggregating as much as ₹121.03 Crores
• Sort: 100% Recent Subject
• Itemizing at: BSE, NSE
• Lead Supervisor: Interactive Monetary Providers Ltd.
• Registrar: Kfin Applied sciences Ltd.

IPO Reservation:

• QIB: Not lower than 75% of Internet Subject
• NII: Not lower than 15% of Internet Subject
• Retail: No more than 10% of Internet Subject

Firm Financials

Key Ratios:

• ROCE: 21.93%
• RoNW: 25.21%
• PAT Margin: 17.06%
• Debt/Fairness: 0.73
• Value to Guide Worth: 4.51

P/E Ratio Comparability with Friends

• Anlon Healthcare IPO P/E: 14.26x (Publish Subject)
• Peer with Highest P/E: Divi’s Laboratories – ~42x
• Peer with Lowest P/E: Aurobindo Pharma – ~17x
• Business Common P/E: ~28x

👉 The IPO is priced attractively in comparison with friends and beneath trade common.

Objects of the Subject

The corporate proposes to make the most of the online proceeds for:

1. Funding capital expenditure for growth – ₹307.19 million
2. Reimbursement/prepayment of sure borrowings – ₹50 crore
3. Working capital necessities – ₹431.5 crore
4. Normal company functions

Gray Market Premium (GMP)

As of as we speak, the Anlon Healthcare IPO GMP is round ₹20-25 per share, indicating constructive investor sentiment. This interprets to an estimated 20-25% itemizing achieve over the difficulty value.

Causes to Put money into Anlon Healthcare IPO

• Sturdy Monetary Progress: PAT grew from ₹5.82 Cr (FY23) to ₹11.96 Cr (10M FY25).
• Enticing Valuation: P/E of 14.26x is beneath trade common.
• Diversified Product Portfolio: APIs and intermediates throughout a number of industries.
• International Market Attain: A number of DMF approvals and exports to regulated markets.
• Debt Discount Plan: IPO proceeds for use partly for mortgage reimbursement.

Danger Components within the IPO

• Dependency on APIs & Intermediates: Enterprise focus threat.
• Excessive Working Capital Requirement: Significant slice of IPO funds allotted right here.
• Regulatory Danger: Enterprise closely depending on world and home pharma rules.
• Business Cyclicality: Demand and pricing can fluctuate with pharma market cycles.
• Low Retail Quota: Solely 10% reserved for retail buyers.

Methods to Apply for Anlon Healthcare IPO?

Traders can apply through:

• ASBA (Financial institution Internet Banking) by way of supported banks.
• UPI (Unified Cost Interface) through brokers and buying and selling apps like Zerodha, Groww, Paytm Cash.

Conclusion – Ought to You Put money into Anlon Healthcare IPO?

Anlon Healthcare IPO comes with a robust enterprise mannequin, sturdy monetary progress, and enticing valuations in comparison with friends. Whereas regulatory and trade dangers stay, the corporate’s sturdy product portfolio and world presence present a aggressive edge. Contemplating the cheap pricing and constructive GMP, this IPO seems good for itemizing features and medium to long-term funding.

Advice: Traders can SUBSCRIBE to the Anlon Healthcare IPO.

FAQs

1. What’s the Anlon Healthcare IPO Date?
The IPO opens on August 26, 2025, and closes on August 29, 2025.

2. What’s the Anlon Healthcare IPO Value Band?
The worth band is ₹86 to ₹91 per share.

3. What’s the Anlon Healthcare IPO Lot Measurement?
One lot consists of 164 shares. Minimal funding for retail buyers is ₹14,924.

4. What’s the Anlon Healthcare IPO GMP as we speak?
At the moment, GMP is round ₹20-25 per share.

5. What’s the Anlon Healthcare IPO Itemizing Date?
Tentative itemizing date is September 3, 2025.

6. Is Anlon Healthcare IPO good or unhealthy for funding?
It seems enticing because of sturdy progress, cheap valuations, and constructive GMP – good for itemizing features and long-term holding.

7. How a lot is reserved for retail buyers in Anlon Healthcare IPO?
No more than 10% of the online challenge.

Suresh KP is a seasoned monetary knowledgeable with over 20 years of expertise. He’s NISM Licensed Funding Adviser and Analysis Analyst. For extra about his experience and certifications, go to About Suresh KP

Newest posts by Suresh KP (see all)

• Anlon Healthcare IPO – Assessment, Date, Value, GMP, Evaluation – Ought to You Subscribe or Keep away from? – August 23, 2025
• 10 Mutual Funds That Crashed the Most within the Final 1 Yr (-14% to -16%) – August 20, 2025
• Mangal Electrical IPO Assessment – Date, Value, GMP, Evaluation – Must you Subscribe or Keep away from? – August 20, 2025